Direct Oral Anticoagulants in Addition to Antiplatelet Therapy for Secondary Prevention After Acute Coronary Syndromes: A Systematic Review and Meta-analysis.

ABSTRACT:

Importance

Patients with acute coronary syndrome (ACS) remain at high risk for experiencing recurrent ischemic events. Direct oral anticoagulants (DOAC) have been proposed for secondary prevention after ACS.

Objective

To evaluate the safety and efficacy of DOAC in addition to antiplatelet therapy (APT) after ACS, focusing on treatment effects stratified by baseline clinical presentation (non-ST-segment elevation ACS [NSTE-ACS] vs ST-segment elevation myocardial infarction [STEMI]).

Data sources

PubMed, Embase, BioMedCentral, Google Scholar, and the Cochrane Central Register of Controlled Trials were searched from inception to March 1, 2017.

Study selection

Randomized clinical trials on DOAC after ACS were evaluated for inclusion. Overall, 473 studies were scree

SUBMITTER: Chiarito M 

PROVIDER: S-EPMC5885890 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature